English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Vitamin B3 and Glaucoma Risk: What New Research Suggests
If you've ever walked out of an eye exam with a slip of paper mentioning elevated intraocular pressure, you know the particular flavor of that worry. Not quite an emergency. Not quite nothing. Your optometrist probably said something reassuring, scheduled a follow-up, maybe suggested drops — and sent you home to spend the next week googling glaucoma at midnight. Here's a wrinkle worth knowing about. A form of vitamin B3 called nicotinamide — the same nutrient that lives quietly in your morning eggs and the tuna sandwich you had last Tuesday — has been quietly gathering scientific attention as something that might help protect the optic nerve. A recent large-scale analysis puts a bit more weight behind that idea. It's not a cure. It's not a replacement for anything your doctor recommends. But it's an interesting piece of the puzzle, and it's the kind of thing worth bringing up at your next appointment. Ocular hypertension is the clinical term for pressure inside the eye that sits higher than what's considered normal, but without the actual optic-nerve damage that would qualify as glaucoma. Think of it as the yellow-light zone. You're not in trouble yet, but the road ahead has a warning sign on it. The reason anyone cares is that elevated eye pressure is one of the biggest risk factors for glaucoma — a condition that quietly damages the optic nerve and is the leading cause of irreversible blindness on the planet. Glaucoma tends to sneak up on people. By the time you notice symptoms, you've usually already lost some peripheral vision, and lost vision doesn't come back. That's why anyone with high pressure gets watched carefully. Drops, laser treatment, and regular monitoring are the standard playbook. What hasn't traditionally been on that playbook is a B vitamin. Which is what makes the newer research interesting. Nicotinamide is one of the two main dietary forms of vitamin B3. The other, niacin, is the one that causes that hot, itchy flush at high doses. Nicotinamide doesn't do that, which is part of why researchers like it — it's well tolerated even at doses well above what you'd get from food. Inside your cells, B3 converts into NAD+, a molecule your mitochondria use to keep energy production humming along. Nerve cells, including the delicate ones in your retina and optic nerve, are especially hungry for that energy. When NAD+ levels drop — which happens with age, stress, and various diseases — those cells become more fragile and more prone to damage. The theory goes that keeping NAD+ topped up might make the optic nerve more resilient to the pressure it's under. That's the lab bench story. The bigger question has always been whether it holds up in real people, in the real world, over meaningful stretches of time. A team of researchers dug into electronic medical records from 67 healthcare organizations across the United States, spanning a twenty-year window. They pulled out 1,460 patients with documented ocular hypertension who had also been taking nicotinamide, and matched them against 1,460 patients with the same condition but no history of nicotinamide or niacin use. Everyone was followed for an average of just under four years. The results were striking. Among the nicotinamide group, roughly 3.5% went on to develop glaucoma. In the control group, that number jumped to 9%. The secondary outcomes told the same story — the nicotinamide users were also less likely to be prescribed pressure-lowering drops and less likely to need laser procedures during the follow-up window. To put that in plain terms: the people taking B3 were not only diagnosed with glaucoma less often, they also seemed to need less escalating treatment along the way. That's the kind of consistent signal that gets researchers' attention. This is the part where I have to slow you down. The study is genuinely encouraging, but it's not a clinical trial. It's what's called an observational analysis, which means the researchers watched what already happened rather than randomly assigning people to take the vitamin or a placebo. That distinction matters. Here's why. People who take supplements tend to differ from people who don't in ways that don't show up in medical records — they might exercise more, eat differently, see their doctors more often, or be more attentive to their health in general. Even with careful statistical matching, those hidden differences can inflate an apparent benefit. Association is not causation, and the study authors themselves are careful to say so. A few other things worth holding in mind: If you're the person this article is aimed at — someone who got the pressure warning and is now looking for anything actionable — here's a practical way to think about it. First, keep whatever your ophthalmologist has you doing. Drops work. Monitoring works. Missing appointments is how small problems become large ones. Second, at your next visit, mention this research and ask whether nicotinamide is something worth adding to your regimen given your specific numbers, family history, and overall health. Some eye doctors are already recommending it; others will want to look at the evidence themselves. Both responses are reasonable. Third, pay attention to the boring, foundational stuff that supports eye and nerve health in general. Blood pressure and blood sugar both influence how your optic nerve fares over decades. Sleep matters, because your eye pressure fluctuates depending on how rested you are. Regular movement helps. So does not smoking. None of this is glamorous advice, but it's the ground floor under any specific intervention you might add. One thing I find quietly hopeful about this research is what it suggests more broadly — that ordinary nutrients, ones we've known about for a century, may still have surprises to reveal. The nervous system is complicated and slow to heal, and any tool that helps keep it resilient is worth investigating carefully. Whether it's B3 for the optic nerve, omega-3s for the brain, or magnesium for a hundred different downstream effects, the basic biochemistry of being a body seems to reward paying attention to inputs most people take for granted. That doesn't mean turning your kitchen into a supplement store. It means treating your annual bloodwork, your eye exams, and your conversations with clinicians as real information — not chores. The people who catch things early tend to be the ones who keep showing up and asking questions. For readers exploring the wider landscape of nervous-system recovery and holistic wellness practices — including plant-medicine and integration retreats that address stress, trauma, and long-term nervous-system regulation — a curated selection can be browsed on our marketplace here. And whatever you decide about the vitamin question, don't skip that follow-up appointment. Your future eyesight is patient, but it's not that patient.
The Billion-Dollar Quarter: What Psychedelic Funding in 2026 Means for Retreat-Goers
A little over a billion dollars flowed into psychedelic drug companies between April and June of 2026. That is not a typo, and it is not a rounding-up of the past decade. It happened in a single quarter. If you're reading this because you're weighing an ayahuasca retreat, an ibogaine program, or a psilocybin ceremony somewhere in the mountains, that number might feel like it lives in a completely different universe from yours. In some ways it does. In other ways, it's about to reshape the world you're stepping into. I've been covering the psychedelics space long enough to have watched three or four hype cycles come and go. This one feels different — not because the money is bigger (though it is), but because clinical results are finally catching up to the promises. And that shift matters for anyone considering a retreat, even if you never plan to swallow a pharmaceutical pill in your life. The headline is simple. Ten financing events. Just over a billion raised. The biggest single round on record in this field. But almost the entire pile came from one company: Definium Therapeutics, an LSD-focused drug developer, which pulled in $805 million on the back of a positive Phase 3 readout showing meaningful antidepressant effects. That is roughly what the entire psychedelics sector raised in some earlier full years combined. The rest of the quarter was quieter, but not sleepy. GH Research, which is developing an inhaled 5-MeO-DMT product, netted around $117.5 million. Helus Pharma — the company formerly known as Cybin — closed a $50 million raise. Smaller players followed: Optimi Health, a psychedelics manufacturer up in Canada, closed a $15 million offering, and Psilera announced $8.8 million in seed funding (with a chunk of that having actually been sitting on the books since 2021, which tells you something about how patient this corner of biotech has to be). Ten deals. One monster round. A handful of solid but unremarkable ones. That's the shape of the quarter in a sentence. Here's the honest answer: it matters less than the headlines suggest, and more than the skeptics claim. Drug developers are chasing FDA approval — meaning standardized doses, tightly controlled clinical settings, and eventually prescription-based access. That world is very, very different from the world of a traditional ayahuasca ceremony in the Peruvian Amazon, or a psilocybin retreat in Jamaica, or an ibogaine clinic in Mexico. A pharmacy in Ohio is not going to hand you a bottle of ayahuasca in 2027. It might, eventually, hand your neighbor a blister pack of synthetic psilocybin for treatment-resistant depression. Those are two separate universes doing two separate things. But the money moving through the pharma side has knock-on effects on the retreat side, whether the retreat industry likes it or not. Research validates the medicine. Media coverage grows. Insurance conversations start. Practitioners get better training. Screening protocols tighten. And — this is the important part — the general cultural conversation shifts from "drugs that ruined the sixties" to "tools that clinical trials keep confirming actually work for depression, PTSD, and addiction." That shift is what you're feeling, quietly, when your therapist doesn't recoil the way she would have five years ago. A billion-dollar quarter creates a specific set of ripples. Some are good for retreat-seekers. Some are worth watching with a raised eyebrow. None of this changes the fundamental question you're actually asking, which is something more like: will this help me get unstuck? But it changes the environment in which you're asking it. One thing worth naming plainly: ayahuasca, San Pedro, iboga, and the mushrooms that grow out of a Oaxacan hillside are not going to be replaced by tablets. The clinical world is chasing molecules — DMT alone, psilocybin alone, LSD alone, 5-MeO-DMT alone. Traditional plant medicine works differently. The ayahuasca vine and its companion chacruna leaf are the classic example: two plants working together, with dozens of trace compounds, prepared by someone whose lineage stretches back generations. That is not a product that scales to a pharmacy shelf, and most curanderos don't want it to. What the funding boom does mean is that the underlying science of what these plants are doing to the brain — how they promote neuroplasticity, why they seem to loosen the grip of addiction, how they interact with trauma processing — keeps getting clearer. If you've ever tried to explain to a skeptical family member why you're considering flying to Peru, that clarity helps. "There are Phase 3 trials showing this works" lands differently than "a friend of a friend had a breakthrough." Both statements can be true. But one of them your dad will listen to. If you're actively researching a retreat — for addiction, for depression, for the sludge that trauma leaves behind, for whatever pattern won't let go of you — the funding news shouldn't change your timeline much. Pharmaceutical psilocybin might reach approval in the next couple of years. Pharmaceutical LSD, with Definium's recent readout, is now genuinely on the radar. But "in a couple of years" is a long time when you're the one struggling now, and even after approval, access will be gated, expensive, and geographically limited for a while. What I'd actually suggest, if you're at that decision point: The money pouring into psychedelic pharma is validating something that indigenous traditions have known for centuries — that these compounds, handled with care, can crack open patterns that talk therapy alone can't reach. What the traditions know that the trials are still catching up on is that the container matters as much as the compound. A trained shaman, a considered set and setting, and a community that holds you afterward — those aren't extras. They're most of the medicine. If you're curious about what's out there and want to see what serious operators actually look like, a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The billion dollars will still be moving next quarter, and the plants aren't going anywhere either.
When a Trip Goes Sideways: What to Do When a Friend Has a Bad Psychedelic Experience
Someone you love takes a psychedelic. Maybe mushrooms at a music festival. Maybe ayahuasca at a retreat you both saved for months to attend. Maybe LSD in a friend's living room on a Saturday night. And somewhere along the way, the trip turns. Their eyes go glassy in a way that isn't wonder anymore. They start repeating a sentence. They curl up. They cry, or they get scared, or they get quiet in a way that makes the room feel colder. What now? This is the question nobody wants to think about before they head off to a ceremony or a festival — and it's the exact question everyone eventually needs to answer. The world of ayahuasca, psychedelics, and master plants isn't all sunrise meditations and breakthrough insights. Sometimes the medicine drags people through territory they weren't ready for. Sometimes a friend goes somewhere hard, and you're the one sitting next to them, watching it unfold, wondering if you're helping or making it worse. Here's what I've learned from sitting in ceremony spaces, from talking with facilitators who've seen it all, and from being the friend on both sides of that hard moment. First, let's ditch the phrase “bad trip.” It's lazy shorthand that lumps together very different experiences — a moment of anxiety, a confrontation with old trauma, a full-blown dissociative crisis. These aren't the same thing, and they don't need the same response. A difficult experience might look like intense fear or paranoia, uncontrollable crying, repetitive movements, feeling trapped in a loop, dissociation from the body, or the conviction that something terrible is happening or has already happened. Sometimes it looks calm on the outside — the person is simply gone, eyes far away, unreachable for a while. None of these are automatically emergencies. Psychedelic states are wildly nonlinear. A person can move from terror to peace to laughter in the space of twenty minutes. The trap most sitters fall into is treating every hard moment like a crisis, when what's actually happening is a healthy — if unpleasant — unfolding. Hard is: crying, shaking, expressing fear, saying things that don't make sense, wanting to be held or left alone, purging on ayahuasca (which is often part of the process), reliving something old. Dangerous is: trying to run into traffic, wanting to hurt themselves or someone else, showing signs of a serotonin or cardiac emergency, having a seizure, taking additional substances mid-experience, or losing consciousness in a way that doesn't fit the substance's normal profile. Dangerous means you call for help, no ego involved. The single most useful thing you can do is regulate your own nervous system. Psychedelic states are famously permeable — the person tripping is picking up on everything around them, including whether you're panicking. If you're calm, they have something to co-regulate with. If you're spiraling, you're pouring gasoline on their fire. Breathe slowly. Sit at their level, not looming over them. Keep your voice low and unhurried. Don't crowd them, but don't disappear either. Your job is to be a steady, unspectacular presence — a lighthouse, not a rescue helicopter. A few practical things that tend to help: The old advice from the Zendo Project — the harm-reduction group that has sat with thousands of people in altered states — boils down to four principles: create a safe space, sit, don't guide; talk through, not down; and difficult is not the same as bad. Those four have never failed me. Ayahuasca deserves its own paragraph here because the difficult moments in a ceremony can look extra alarming to anyone who hasn't seen them before. People purge — sometimes for hours. People wail. People say things in languages they don't speak. People appear to fight invisible things. To an outsider it can look like a horror film. To an experienced facilitator, most of it is just Tuesday. This is one of the strongest arguments for choosing a legitimate retreat with real Amazonian lineage rather than a rented Airbnb and a stranger with a jar of brew. In a proper ceremony, a curandero or curandera is reading the room constantly. They know the songs — the icaros — that can steady someone spinning out. They know when to sit closer, when to sing louder, when to move a person to a different spot in the maloca. That skill isn't decorative. It's the difference between a hard night that becomes medicine and a hard night that becomes trauma. If you're considering a ceremony and worried about the difficult scenarios, the honest answer is: don't go alone, and don't go cheap. Ask retreat centers directly what their protocols are for someone in acute distress. A reputable place will have a clear answer. A sketchy one will get defensive. Here's the part almost nobody prepares for. The trip ends. Your friend is exhausted, quiet, maybe embarrassed, maybe blank. The temptation is to move on — make breakfast, laugh it off, pretend the strange night didn't happen. Don't. The 72 hours after a difficult psychedelic experience are the most important stretch of the whole thing. This is when the raw material either gets metabolized into insight or gets stuffed into a box that will rattle for years. What people who've done real healing work with plant medicine and psychedelics for addiction, depression, or trauma will tell you — almost universally — is that the medicine cracks something open, and integration is what turns that opening into change. Some things that help during integration: If the experience surfaced something the person is genuinely struggling with — flashbacks, persistent anxiety, intrusive imagery lasting more than a few weeks — that's a signal to work with a professional, not to tough it out. Most cities now have therapists who specialize in psychedelic integration. They exist because this need is real and increasingly common. None of what I've written should scare you off. Difficult moments are part of the territory, and the vast majority of them are exactly where the healing lives. The people I know who credit ayahuasca or psilocybin with pulling them out of addiction, depression, or a long stuck patch almost always tell the same story: it wasn't the pretty visions that changed them. It was the night they thought they were dying, and the moment on the other side of it. What matters is the container. Who is holding the space. Whether there's someone there who's seen a hundred hard nights and knows the difference between a soul working itself out and a body in trouble. Whether integration is built into the program or you're on your own the moment you land back home. Ask hard questions before you book. Talk to past participants. Read reviews with a suspicious eye — anywhere with only glowing five-star reviews is either brand-new or curating heavily. If you can, talk to the facilitator directly before committing. Trust your gut. The right retreat feels grounded, not glamorous. For readers who want to take this further, a range of vetted ayahuasca and psychedelic retreats can be browsed on our marketplace here. Wherever you end up, may your difficult moments — the ones you have and the ones you sit with for others — turn into the kind of medicine that actually changes something.
Extreme Fear on 5-MeO-DMT: What It Means and How to Move Through It
There's a moment, roughly fifteen seconds after the vapor hits the lungs, when some people encounter something that words don't really cover. Not a bad trip in the classic sense. Not visuals melting into visuals. Something more like being shoved off the edge of everything you thought you were, with no handrail and no warning. Fear on 5-MeO-DMT — the psychedelic secretion from the Sonoran Desert toad, sometimes called bufo — can be absolute. And it's one of the least discussed corners of the whole plant medicine conversation. If you've been researching a bufo ceremony, or you've already had one and you're still shaken by what happened, this is for you. Not a sales pitch. Not mysticism dressed up in modern clothes. Just what I've seen, what facilitators have told me, and what the people who've been through it tend to wish they'd known first. People who've done ayahuasca, psilocybin, LSD, even smoked N,N-DMT often walk into a 5-MeO ceremony thinking they know the territory. They don't. The two DMTs share three letters and almost nothing else experientially. Ayahuasca unfolds over hours, gives you room to negotiate, lets you sit with imagery and memory. 5-MeO strips the negotiation table away. In the reports I trust most, there is no self left to negotiate with. That's the point. And that's also what makes it terrifying for a not-insignificant number of participants. The onset is fast — under a minute — and the peak arrives before your body has caught up with the fact that anything is happening. Some people describe it as a kind of white light or oceanic dissolution. Others describe pure, wordless panic. Both are considered normal reactions in the underground and clinical communities that work with the medicine. The problem is that most retreat marketing shows you the first version and skips over the second. The fear on 5-MeO isn't usually the same as a difficult mushroom trip, where a scary thought loops and you can talk yourself down. It's more like the fear of ceasing to exist — because in some sense, for a few minutes, you kind of are. Ego death sounds poetic in a podcast. Lived from the inside, it can feel like dying. Your body may thrash, freeze, moan, or go completely still. You may believe, in that moment, that you will never come back. You always do. But no article can convince a nervous system mid-experience of that. Here's the honest answer: a strong fear response on 5-MeO-DMT is common enough that experienced facilitators plan for it. It doesn't mean you got a bad batch, a bad ceremony, or that you're psychologically broken. It usually means one of a few things. Any one of those is enough. Two or three together and terror becomes almost predictable. The medicine itself isn't punishing you. It's showing you the location of the resistance with extraordinary precision. Studies on 5-MeO-DMT are still thin compared to psilocybin or MDMA, but survey data from Johns Hopkins and other groups suggests that a meaningful minority of participants report challenging experiences — including fear, panic, and lingering psychological difficulty in the days after. Most also report significant reductions in depression and anxiety weeks later. Both things can be true. The medicine can hand you the worst hour of your life and, months later, you may say it was one of the most important. I'm not romanticizing that. I'm telling you what the data and the interviews consistently show. People often ask what they can actually do to reduce the odds of a terrifying journey. The truthful answer is: a lot, but not everything. You don't control the medicine. You control the container you bring to it. Preparation for 5-MeO isn't the same as prepping for ayahuasca. You're not doing weeks of dieta with master plants. You're doing something more like preparing for a very intense meditation retreat compressed into fifteen minutes. That means nervous system work, not just intention-setting worksheets. The people I've interviewed who report the smoothest journeys almost always share one trait: they had done meaningful work on their nervous system before the ceremony, not just their mindset. Belief that you're ready is not the same as being ready. If you're reading this because something happened and you're still rattled — days, weeks, or months later — please know that integration matters more than the experience itself. The 5-MeO community has gotten better at this, but it's still uneven. Some retreat centers send you home the next morning with a hug and a smoothie. That's not enough. Real integration after a fear-heavy 5-MeO experience usually involves: If you're experiencing lingering symptoms — dissociation, persistent anxiety, intrusive re-experiencing — treat it seriously. It's rare, but it happens, and it's not shameful. It's a medical situation that deserves proper support. This is where the retreat you pick matters most. A skilled 5-MeO facilitator has sat with hundreds of people, many of them terrified, and knows how to stay grounded while someone else's world dissolves. You want someone who has training in psychological first aid, who works with a small group or one-on-one, who doesn't push higher doses, and who has integration support built into the offering — not tacked on as an upsell. Questions worth asking before you book anything: If the answers are vague, or you're being sold on transformation before safety, keep looking. There are careful, experienced practitioners in this space, and there are people who found out about bufo eighteen months ago and started charging for ceremonies. The gap between them is enormous. Here's the part that took me a while to accept. Fear on 5-MeO-DMT isn't a sign that psychedelic healing failed you. Fear is often the material. The medicine is showing you where you're bracing against your own life, and it's doing it at a speed the mind can't manage. Whether that becomes a breakthrough or a wound depends less on the substance and more on what surrounds it — the facilitator, the setting, the preparation, the integration. Plenty of people who had terrifying first experiences with bufo have gone on to describe it as pivotal. Others have decided, sensibly, that this particular medicine isn't for them, and moved toward slower work with ayahuasca, psilocybin, or non-psychedelic approaches. Both choices are valid. The one choice that isn't valid is going in blind because a friend said it changed their life. For readers who want to keep exploring this carefully, a range of vetted 5-MeO-DMT and broader plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're actually ready.
Psilocybin and Antidepressants: What You Need to Know Before a Retreat
Somewhere in the intake form for almost every psilocybin retreat you'll find a section that quietly asks about your current medications. Most people gloss over it. They shouldn't. If you're on antidepressants — SSRIs, SNRIs, tricyclics, MAOIs, lithium, bupropion, or one of the newer additions to the psychiatric shelf — the interaction between your prescription and a ceremonial dose of psilocybin is one of the most important conversations you'll have before you ever sit in circle. This isn't a moralizing piece about staying on or coming off medication. That's between you and a prescriber who actually knows you. What this is — is a plain-English walkthrough of what happens biochemically, what facilitators tend to require, what the risks actually look like, and how to think about all of it without either panicking or shrugging it off. If you're considering a psychedelic retreat and you take something daily to manage depression, anxiety, or a mood disorder, keep reading. This one matters. Psilocybin, once metabolized into psilocin, works largely by binding to serotonin 2A receptors in the brain. That's the same neurotransmitter system most antidepressants target — just from a very different angle. SSRIs (Prozac, Zoloft, Lexapro, Celexa) keep more serotonin floating in the synapse. SNRIs (Effexor, Cymbalta) do the same for serotonin and norepinephrine. MAOIs prevent the breakdown of serotonin altogether. When you introduce a serotonergic psychedelic into a system that's already been chemically retuned around serotonin, you get a collision of pharmacology that behaves differently depending on which medication is in the mix. The most-repeated concern in retreat circles is attenuation — the psychedelic experience gets muted, sometimes to the point of feeling nothing at all. Your receptors, in effect, have been sitting in a bath of serotonin for months or years and have downregulated. Psilocin arrives, knocks on the door, and the door barely opens. Participants pay thousands of dollars, fly to Peru or the Netherlands or Jamaica, drink the tea or eat the mushrooms, and report a mild body sensation and not much else. It's a real phenomenon, and it's the reason many retreats won't accept guests still actively taking SSRIs. Attenuation is the disappointing outcome. The dangerous one is serotonin syndrome — a rare but serious condition where serotonin levels spike beyond what the body can handle. Symptoms range from sweating and confusion to muscle rigidity, seizures, and, in extreme cases, death. The higher-risk combinations involve MAOIs (which is why ayahuasca is a hard no with most antidepressants — the vine itself contains MAOIs) but tricyclics and certain SNRIs also raise the risk profile. The details matter more than most blog posts admit. Here's a rough map of the terrain: None of the above is a prescription — literally. It's a summary of what the current literature and retreat community consensus suggest, and it changes as more research comes in. The specifics of your dose, your body, your other medications, and your history all shift the picture. This is the question that lands in facilitator inboxes constantly, and the honest answer is: not on your own, and not casually. Discontinuation syndrome is real. Coming off an SSRI or SNRI abruptly can produce weeks of dizziness, brain zaps, insomnia, emotional volatility, and — for some people — a full return of the depression the medication was managing, sometimes worse than before. A responsible taper is done with the prescriber who put you on the medication in the first place. Weeks, sometimes months, of stepping the dose down. Some people navigate it beautifully. Others discover their depression was more medication-dependent than they realized. Neither outcome is a failure — but discovering it two weeks before a booked ceremony in the jungle is a bad time to find out. Here's the piece I wish more people considered before booking: you may not be a good candidate for a psychedelic retreat right now, and that's not a verdict on your future. If your medication is doing meaningful work stabilizing you, ripping it away to chase a mushroom experience can undo months of hard-won ground. Retreats will still be there next year. Your nervous system's stability is not a renewable resource you should gamble. A well-run psychedelic or plant-medicine retreat will send you a medical intake form that reads like a small novel. They'll ask about every prescription, over-the-counter medication, supplement, and recreational substance. They'll want dosages, duration, and the name of your prescribing doctor. Some require a signed letter from that doctor clearing you for participation. If a retreat doesn't ask these questions, that's a red flag the size of a billboard. It means they're either negligent or willing to take on liability they shouldn't. Either way, not the container you want to be in when you're chemically vulnerable and hours from your ordinary reality. Expect a good retreat to require: The microdosing question deserves its own paragraph because it comes up constantly. Subperceptual doses of psilocybin — the 0.1 to 0.3 gram range — theoretically pose less risk of the acute problems associated with a full ceremonial dose. But the theoretical part is doing a lot of work in that sentence. The research on chronic low-dose interactions with SSRIs is thin. Anecdotal reports on Reddit and elsewhere suggest people do it, but anecdotal reports also suggest people do all kinds of things without incident until they don't. The more thoughtful position is: microdosing while on serotonergic antidepressants likely does something, we don't fully know what, and the people best positioned to answer the question — psychiatrists trained in psychedelic medicine — are still a small and geographically clustered group. If you can find one, talk to them. If you can't, err on the side of not experimenting on yourself with two active compounds whose interaction hasn't been mapped. Most people asking about medication interactions are really asking a different question: am I too damaged, too medicated, too far into pharmaceutical territory to still benefit from plant medicine? The answer is no. Some of the most profound retreat stories I've heard came from people who spent a decade on antidepressants before they were ever ready — practically or medically — to try something else. The path there just isn't the fastest one. It usually involves a slow, deliberate reworking of your medication regimen with a doctor who takes psychedelics seriously as a treatment modality (they exist, and there are more every year), a period of stabilization off medication before ceremony, and honest conversations with facilitators about your history. Rushed, this path gets people hurt. Patient, it opens doors that were previously locked. If you're at the beginning of researching this and want to see what responsible facilitation actually looks like, a curated selection of psilocybin and plant-medicine retreats — the kind that ask the hard medical questions before taking your booking — can be browsed on our marketplace here. Read the intake requirements carefully. The retreats worth attending are the ones that might tell you to wait.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
When Chronic Illness Breaks You: Finding Real Healing Beyond the Hyper-Vigilance
There's a specific exhaustion that comes from living inside a body you can't fully trust. People who've spent decades managing a chronic condition know it well — the low hum of vigilance that never really switches off, the way your shoulders sit half an inch higher than everyone else's, the running mental checklist that keeps you tethered to the next possible threat. It looks a lot like anxiety from the outside. Underneath, it's something older and stranger. It's the nervous system deciding, quite reasonably, that the world is not safe. I've spent a lot of time in retreat spaces sitting next to people who arrived carrying exactly this. Severe allergies. Autoimmune conditions. Long COVID. Chronic pain that no scan could explain. What they had in common wasn't the diagnosis — it was the pattern that grew up around the diagnosis. A pattern that, in many cases, was doing more damage than the original illness by the time they showed up looking for help. This post is for people living inside that pattern, or loving someone who is. I want to talk honestly about how chronic illness rewires the nervous system, why traditional talk therapy sometimes stalls on it, and where practices like meditation, community, and — yes — plant medicine can actually move the needle. No promises. No hype. Just what I've seen and what the science increasingly supports. Most people underestimate how much cognitive real estate a chronic condition eats up. If you've grown up scanning restaurants for allergens, reading every label twice, mentally locating exits in unfamiliar rooms — that scanning becomes the substrate of your daily consciousness. It's not something you do. It's who you are. And when the reactions are severe enough to be life-threatening, a whole other layer settles in: the awareness that any lapse could be your last. Clinicians increasingly recognise this as a form of post-traumatic stress. It doesn't require a single defining event. It builds from the drip-feed of near-misses, ER trips, and the small daily humiliations of being the person who has to make everyone stop and read the menu again. One woman I met on a psilocybin retreat in the Netherlands described it perfectly: “I've been performing calm for so long, I forgot my body was allowed to relax.” The knock-on effects are predictable and brutal. Sleep goes first. Then appetite, or the ability to trust food at all. Social life contracts. Some people develop full-blown agoraphobia; others just quietly stop saying yes to things. And because the underlying illness is real — the allergen really can kill you, the pain really is unpredictable — the vigilance never feels irrational. That's what makes it so hard to unwind. Talk therapy helps. So do SSRIs, for some people. Cognitive behavioural approaches can chip away at the more obvious catastrophising loops. But for a lot of chronic-illness patients I've spoken with, these tools only get them so far. The problem isn't primarily cognitive. You can know, intellectually, that the restaurant is safe. Your body still won't let you eat. This is where the newer wave of somatic and psychedelic-assisted approaches comes in. The nervous system that's been in threat mode for twenty years needs more than a reframe — it needs a felt experience of safety, sustained long enough that something below the neck starts to believe it. That's a very specific kind of work. None of these are magic bullets. All of them require time, decent guidance, and a willingness to be uncomfortable. But when they work, they work at a depth that talk alone rarely reaches. Let me be careful here, because this is where a lot of nonsense gets written. Plant medicines — ayahuasca, psilocybin, San Pedro, ibogaine — are not treatments for allergies, autoimmune conditions, or any physical illness. Anyone telling you otherwise is either uninformed or selling something. What plant medicine can sometimes address is the psychological and nervous-system fallout that grows around a chronic condition: the trauma, the hyper-vigilance, the disordered relationship with your own body. The mechanism, as best current research understands it, involves a temporary increase in neuroplasticity — the brain's ability to form new connections and, crucially, to consider new interpretations of old experiences. During an ayahuasca ceremony, someone who's spent decades braced against their body might, for the first time in memory, feel their body as a home rather than a threat. Not because the illness has gone anywhere. Because the relationship to the illness has shifted. I've watched this happen. A man in his fifties, career derailed by chronic pain, spending most of a psilocybin retreat weeping quietly and then telling the circle on the last morning that he'd forgotten his body could feel anything other than an enemy. Whether that shift holds depends almost entirely on what he does in the six months after — the integration work, the community, the daily practices. The ceremony cracks the door. Walking through it is a longer job. If you're living with a chronic condition and considering a plant-medicine retreat, the vetting process needs to be more rigorous than it would be for someone in robust health. This is not a place to cut corners. A few things to look for: You'll notice these questions are basic. That's the point. If a retreat can't answer them clearly and without defensiveness, they're not the right fit — not because they're necessarily unsafe, but because you specifically need more than they're offering. Here's the thing nobody wants to hear: the retreat is the easy part. The hard part is the year afterwards, when the insights are supposed to translate into changed behaviour and mostly don't, unless you build the scaffolding for them to land on. Community shows up again and again as the most consistent predictor of who actually rebuilds their life after a difficult experience — chronic illness, addiction, trauma, take your pick. Not community in the vague inspirational sense. Specific people who understand what you've been through and don't need you to explain the baseline. For someone with severe allergies, that might be one friend who has the same condition and gets it without translation. For someone recovering from addiction, it might be a sponsor and a room full of people in the same boat. The people I've seen make the deepest changes tend to combine three things: a serious psychedelic or contemplative experience, ongoing daily practice (meditation, movement, breathwork — pick your medicine), and a small circle of people who can hold them accountable and witness the change. Take away any one leg and the stool tends to wobble. Most of the people I've met who've genuinely healed from the psychological weight of a chronic condition arrived at the same unglamorous conclusion. They stopped fighting the fact of the illness. Not resignation — something more active. A decision to build a life around the reality of the body they have, rather than the body they wish they had. Plant medicine can accelerate that recognition. So can years of therapy, or a good meditation practice, or a truly difficult conversation with someone who loves you. There's no single right doorway. There's just the doorway that opens for you, when it opens, and the work of walking through it. If any of this resonates and you're weighing whether a plant-medicine retreat might be part of your own path, curated ayahuasca, psilocybin, and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The right retreat, at the right moment, with the right preparation, is worth waiting for.
Psychedelics and Contemplative Practice: Where Plant Medicine Meets Meditation
There's a question that keeps circling back in the plant medicine world, and it's not going away. Can psychedelics and contemplative practice actually work together, or are they two different paths pretending to share a map? Anyone who's sat in an ayahuasca ceremony after years of meditation — or tried to meditate the week after one — knows this isn't a theoretical question. It's a lived one. The conversation around psychedelics, master plants, and consciousness has moved a long way from the fringes. Clinical trials are looking at psilocybin for depression. Ibogaine clinics are quietly pulling people out of decades of addiction. Ayahuasca retreats are booked six months out. And running underneath all of it is a much older current: the contemplative traditions that have been mapping inner experience for thousands of years without any chemical help at all. If you're reading this, you're probably somewhere in the middle of a decision. Maybe you've meditated for years and you're wondering whether a psychedelic retreat would open something the cushion hasn't. Maybe you've had a big ayahuasca experience and you can't figure out how to hold it — how to bring it into a Tuesday afternoon. Either way, the two worlds are asking the same underlying question: what is this mind, and what happens when it lets go of its usual grip? The interesting thing is that until recently these two communities barely spoke to each other. Meditators treated psychedelics as a shortcut, or worse, a cheat. Psychedelic enthusiasts treated meditation as slow and dry. Both were half right and half missing the point. What's happening now — in retreats, in research, in living rooms — is that people are actually comparing notes. Sit with a serious meditator for long enough and they'll describe states that sound uncannily like a moderate psychedelic experience. Dissolution of self. Time going strange. A sense that consciousness is not a private little thing inside a skull but something wider, thinner, more shared. Sit with someone who's done ten ayahuasca ceremonies and they'll describe insights that any Zen teacher would nod at. The territory looks similar. The vehicles differ. Here's the thing that took me years to notice: the plant medicine tradition and the contemplative tradition are pointing at the same territory from opposite directions. Contemplative practice is slow, patient, cumulative. It builds a stable platform. Psychedelics — ayahuasca, psilocybin, San Pedro, ibogaine — crack the door open faster and wider, but they don't necessarily give you the muscle to stay in the room. Which is why so many facilitators now recommend some form of contemplative practice alongside plant medicine work. Not because meditation makes ceremony more spiritual (that's marketing talk), but because it gives you somewhere to put what happens next. In Amazonian shamanism, master plants aren't just pharmacology. They're understood as teachers — individual intelligences that a person diets with, sometimes in isolation, sometimes over years. Ayahuasca is the most famous of them, but there are dozens: chacruna, chiric sanango, ajo sacha, bobinsana, tobacco. Each one is said to teach something different. Bobinsana teaches heart-opening. Tobacco teaches grounding and protection. Ayahuasca teaches, well, ayahuasca teaches whatever it decides you need to see. The concept is strange to a Western mind at first. A plant, teaching? But if you sit with it long enough, something shifts. You start noticing that the encounter isn't quite what you assumed. It's not that the plant is a pharmaceutical that produces effects. It's more that the plant introduces a relationship, and the relationship changes you. This is where the contemplative frame becomes useful. If you approach plant medicine with the same attitude you'd bring to a serious meditation retreat — patience, humility, willingness to sit with discomfort — the experience tends to be more coherent. If you show up looking for a fireworks show, you might get one, but you probably won't be able to metabolize it. Anyone considering plant medicine for addiction is asking a specific version of this question. Can a substance help me get free of substances? The evidence — and I mean both the clinical trials and what long-time facilitators have watched happen in ceremony — increasingly says yes, but with major asterisks. Ibogaine has the strongest track record for opioid addiction. It's an intense, medically-monitored experience, not a retreat weekend, and it can genuinely interrupt withdrawal in ways nothing else does. Ayahuasca has shown promise for alcohol dependence and stimulant addiction, particularly when combined with sustained integration. Psilocybin has been studied for tobacco addiction with encouraging results. But here's what people miss: the substance is the smallest part of it. What actually breaks the addictive pattern is what happens around the experience — the preparation, the container, the group, the therapist or facilitator, and the months of integration afterward. Take away those pieces and you have a chemical event with no scaffolding. Recovery isn't a single ceremony. It's what you build after. Skip any of those and the odds drop fast. This is why the retreat you choose matters far more than the specific medicine. Meditators who go into ayahuasca or psilocybin work often report a surprising thing: the experiences are less overwhelming than they expected. Not because they're less intense, but because the meditator has built a certain equanimity — a willingness to observe strong sensation and strong emotion without flinching. That capacity translates directly. The reverse is also true. People who've had big psychedelic openings often find their meditation practice suddenly makes sense in a new way. What used to feel like boring homework becomes an ongoing exploration of the territory the medicine showed them. The two practices become one practice, split across two speeds. None of this is a rule. Some experienced meditators have chaotic ceremonies. Some first-timers with no practice at all have profoundly grounded ones. But as a general pattern, contemplative background helps. If you're planning a retreat and you have zero meditation experience, starting even a modest daily practice a few months out is one of the highest-leverage things you can do. The psychedelic retreat industry has exploded, and not all of it is trustworthy. Some places are genuinely serious about what they're doing. Others are luxury tourism with a shaman decal. Before you send anyone money, ask specific questions. Red flags include guarantees of specific outcomes, pressure to book immediately, no medical screening at all, and facilitators who talk more about themselves than about the medicine. Trust that instinct if something feels off. There will be another retreat. The part that surprises most first-timers isn't the ceremony. It's the two weeks after. You come home and everything looks slightly different, and no one around you has any framework for what you just went through. This is where people either build on their experience or lose it. Integration is where contemplative practice earns its keep. Twenty minutes of sitting each morning. A journal you actually write in. A therapist who understands non-ordinary states, or at least doesn't pathologize them. A friend or two who's been through their own version. These are the unglamorous ingredients that turn a peak experience into a durable change. If none of that infrastructure is in place when you get home, the insights fade within a month. Not entirely — something usually stays — but the specific, actionable clarity you had at the retreat becomes a memory rather than a way of living. Build the scaffolding before you go, not after. The conversation between psychedelics and contemplative practice is still young. Neither tradition has fully absorbed the other, and honestly, that's probably healthy. They're supposed to remain distinct. But for the person sitting where you're sitting — considering a retreat, wondering if plant medicine could shift something that's been stuck for years — the practical takeaway is simple. Prepare well. Choose carefully. Integrate seriously. Treat the medicine with the same respect you'd bring to any serious teacher. If any of this resonates and you want to see what's actually available, a curated selection of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the choice. The right retreat, at the right moment, with the right preparation, can be one of the most meaningful things you ever do — and that's exactly why it's worth being careful about.
The Wellness Trap: What Mindfulness and Plant Medicine Can't Actually Fix
Three in the morning. You're scrolling again. Somewhere between a meditation app notification and an ad for adaptogenic mushroom coffee, you catch yourself wondering: how did I end up with sixteen wellness practices and still feel like this? You're not alone. And you're not doing it wrong. What you're bumping into is something quieter and more interesting than personal failure — it's the way our culture has quietly turned every contemplative practice, every plant medicine, every breathwork protocol into a product that promises to fix you. Mindfulness gets marketed this way. So does ayahuasca. So do psychedelics generally. And the promise, always, is the same: sit with this, drink this, breathe this, and the ache will go. It won't. Not the way the marketing suggests. And understanding why is, in my experience, one of the most important things to get straight before you spend two thousand dollars flying to Peru or three months building a daily practice you'll abandon by March. Mindfulness didn't start as a wellness category. For centuries it was a slice of Buddhist practice — one tool inside a much larger ethical, communal, philosophical framework. Teachers like Sharon Salzberg, Jack Kornfield, and Joseph Goldstein carried Vipassana into Western rooms in the 1970s and 80s. Jon Kabat-Zinn built the clinical bridge with MBSR, showing hospitals that eight weeks of sitting could measurably reduce stress markers in chronic pain patients. Then something happened. The practice got unbundled from its context. It slid from meditation halls into HR departments, from monasteries into corporate offsites, from a lifelong discipline into an eight-minute app session between meetings. And somewhere in that migration, the word mindful stopped describing a quality of attention and started functioning as a prefix that made anything sound healthier. Mindful eating. Mindful parenting. Mindful productivity. Mindful spending, for god's sake. The same thing is happening — right now, in real time — to ayahuasca and psilocybin. What was ceremony is becoming content. What was decades of a curandero's apprenticeship becomes a weekend package with airport pickup. This isn't inherently corruption. Access matters. But the packaging always changes the thing inside the package, and it's worth naming that out loud. Here's the tell: when a practice becomes a label, the label starts doing the work the practice used to do. You buy the mindfulness app and feel virtuous. You book the ayahuasca retreat and feel like you're finally taking your healing seriously. The transaction itself starts to feel therapeutic — which is a beautiful trick if you're selling something, and a genuinely lousy deal if you're the one hoping to change. I've watched this play out at retreats I've sat at. People arrive with a shopping list of things they need the medicine to fix. The divorce. The drinking. The father. The career. They've done the reading. They've listened to the podcasts. And they've been told, sometimes explicitly and sometimes by implication, that one week in a maloca will handle it. What happens next is almost always the same. The medicine shows them something real. Sometimes shattering. They cry, they see, they feel the outline of a different life. Then they fly home, and within six weeks the old shape reasserts itself, because the medicine was never the point. It was the doorway. What they needed to do was walk through — and walking is a thing you do with your legs, in daily life, over years. This is probably the single most-searched question in this whole space, and it deserves a careful answer. The short version: ayahuasca and other plant medicines can be extraordinarily useful adjuncts to healing from addiction, depression, and trauma. The clinical research on ibogaine for opioid dependence is genuinely striking. Studies on psilocybin for treatment-resistant depression have moved regulators. Anecdotally, people leave well-run ayahuasca retreats with insights that reshape years of therapy. But useful adjunct is a very different sentence from cure. The people I've seen make durable changes after plant medicine share a few things in common: The people who came back disappointed, or worse, destabilized, almost always shared the opposite pattern: no preparation, no integration, no community, and a quiet expectation that the plant would do what a decade of unaddressed conditions had not. This is the wellness trap in its most expensive form. There's a phrase in contemplative circles — spiritual bypassing — that describes using spiritual practice to avoid rather than meet unresolved emotional or psychological material. Meditation can do this. So can plant medicine. So can yoga, breathwork, and every other tool in the box. Bypassing looks like calm on the outside. Serene, even. Inside, though, the person is often using the practice to skip over grief, rage, or terror they don't want to touch. The retreat becomes a way of feeling healed without doing the messier work of being healed. And the tragedy is that these are the people most likely to book the next retreat, and the next, chasing the initial glimpse that seemed to promise everything. If you notice you're drawn to plant medicine partly because you don't want to sit with a specific therapist and discuss a specific thing, that's worth paying attention to. Not as a reason to avoid the medicine. As a reason to also — not instead — do the harder, less exotic work alongside it. Let me be more concrete, because I don't want to leave you thinking the whole enterprise is snake oil. A well-run ayahuasca or psilocybin retreat can genuinely offer things ordinary life can't easily produce: Notice that none of these are cures. They're openings. Whether they lead anywhere depends almost entirely on what you do in the weeks and months that follow. If you're weighing a retreat, a few honest filters worth applying before you send a deposit: These aren't glamorous questions. They're the ones that separate a genuine healing container from an expensive vacation with visions. Kabat-Zinn has said, many times, that mindfulness is not a technique but a way of being in wise relationship with experience as you find it. That framing is worth borrowing for plant medicine too. Ayahuasca is not a subtraction of suffering. It's a way of meeting your life more honestly than you usually can. The old teachings are pretty clear-eyed about this. Pain isn't optional. Loss isn't optional. Aging isn't optional. What we have some influence over is our relationship to those things — the story we build, the actions we take, the community we belong to, the causes we address and the ones we accept. Mindfulness offers tools for that relationship. So do the master plants, in their more thunderous way. Neither one exempts you from being a person in a difficult time. The wellness trap, in the end, isn't about any specific practice. It's about the moment you outsource your own agency to a product — an app, a supplement, a retreat, a teacher, a plant — and wait for it to hand you back a fixed self. That waiting is the trap. The work is quieter and more ordinary than the marketing suggests: showing up, again and again, to a life that includes both the joy and the catastrophe, and letting whatever practice you've chosen support you in staying present for both. If some of what's here resonates, and you're seriously considering plant medicine as one honest piece of a larger process rather than a shortcut around it, a range of vetted ayahuasca and psychedelic retreats can be explored on our marketplace here. Take your time choosing. The right container is worth the wait.
Sobriety and Plant Medicine: Rebuilding After Quitting Alcohol
The first ninety days without alcohol are strange. Not bad, exactly. Just strange. You sleep harder than you have in years, wake up early with a clarity that borders on uncomfortable, and start noticing things — the low hum of anxiety you'd been drowning, the resentment you'd been softening, the grief you'd been diluting one glass at a time. People talk about sobriety like it's the finish line. It isn't. It's the moment the actual work becomes visible. Which is why more and more people who've quit drinking end up quietly Googling something like ayahuasca for addiction or psilocybin retreats for sobriety. Not because they want to swap one substance for another — most are terrified of that — but because they suspect there's something underneath the drinking that never got addressed. And they're usually right. Alcohol is a coping mechanism dressed up as a social lubricant. Take it away and the coping doesn't vanish — it just loses its favourite tool. This is why so many people white-knuckle their way to six months sober and then find themselves depressed, restless, or drawn to some new fixation. Work. Food. Scrolling. A new relationship that feels suspiciously urgent. The nervous system that reached for a drink at 6pm every day was reaching for a reason. Sometimes the reason is trauma. Sometimes it's chronic low-grade depression. Sometimes it's a life that quietly stopped fitting years ago and you never wanted to face it sober. Traditional recovery programs are wonderful at community and structure, but they don't always get near the root. That's where a lot of people start looking sideways at plant medicine. The short answer is: the evidence is stronger than most people realise, and more limited than the enthusiasts claim. Somewhere in the middle is the honest picture. Johns Hopkins ran a psilocybin trial for alcohol use disorder that produced results serious enough to make even conservative addiction researchers pay attention — roughly a doubling of the reduction in heavy drinking days compared to placebo. Ibogaine, a West African root, has been used for decades in Mexico and other jurisdictions to interrupt opioid dependence, with unusual efficacy at breaking physical withdrawal. Ayahuasca, though harder to study because ceremonies vary so widely, keeps producing the same anecdotal pattern: people arrive with a decades-long drinking or drug habit and leave with the compulsion noticeably quieter, sometimes gone. None of this is a magic wand. Anyone who tells you otherwise is either selling something or hasn't seen enough people go through it. What plant medicine seems to do, when it works, is loosen the grip of the story that keeps the addiction alive. You suddenly see, very clearly, what you've been running from. Whether the change lasts depends almost entirely on what you do in the months afterwards. Ayahuasca gets most of the headlines, but in the Amazonian tradition it's part of a larger family of what curanderos call master plants — plant teachers with distinct personalities that work on different aspects of a person. Chacruna, chiric sanango, ajo sacha, bobinsana, tobacco (yes, real tobacco, used in radically different ways than we use it in the West). A serious dieta with any of these is nothing like a weekend retreat. It's weeks of isolation, restricted food, no salt, no sugar, no sex, no reading — just you and the plant. Most Westerners never do a full dieta. They come for a five or seven night ayahuasca retreat, drink the brew three or four times, and go home. That's a legitimate entry point, but it's worth understanding you're getting a taste of a much deeper tradition. The ceremony itself — the mareacion, the icaros the shaman sings, the purging, the visions — is the part that gets described in memoirs. The quieter, longer work of integrating what you saw is the part that actually matters for someone in recovery. Here's where I'll be blunt, because this decision deserves it. If you've been sober less than six months, most reputable facilitators will ask you to wait. Not because ayahuasca or psilocybin will make you relapse — usually the opposite — but because early sobriety is fragile in ways you may not fully appreciate yet. A powerful psychedelic experience while your nervous system is still recalibrating can be destabilising. Give yourself a foundation first. When you are ready, here's what actually matters when choosing a retreat: Cost varies wildly. A week-long ayahuasca retreat in Peru typically runs anywhere from around $1,200 at a rustic centre to $4,000+ at a well-staffed facility with medical support. Ibogaine treatment, because of the medical monitoring required, runs higher — often $6,000 to $10,000 for a week. Psilocybin retreats in legal jurisdictions like the Netherlands or Jamaica sit somewhere in between. The retreat is not the healing. This is the sentence I wish someone had tattooed onto my forearm before my first ceremony. The retreat is a doorway. What you do in the weeks and months after — how you sleep, who you talk to, what you stop doing, what you start doing — is the actual medicine. People who do well after plant medicine tend to build a boring, unglamorous scaffolding around the experience. They keep therapy going. They journal, even badly. They stay off alcohol for at least a good stretch afterwards (many find they don't want it anyway). They find one other person who's been through something similar and can talk to them honestly. They resist the urge to immediately book the next retreat, because chasing the peak experience is its own kind of drinking. People who don't do well tend to treat the ceremony as the answer and then wonder why, six months later, the old patterns are creeping back. The plants show you things. They don't do the work of changing you. You do that, slowly, in the ordinary Tuesday afternoons that follow. If you've stopped drinking recently and you're reading this, take the win first. That's not a small thing. Whatever pulled you into that habit had its reasons, and whatever pulled you out of it took real courage. Plant medicine may or may not be part of your next chapter. It's one path, not the path. Some people rebuild through therapy, community, running, prayer, a dog, a garden, a change of city. All valid. But if the pull toward exploring ayahuasca, psilocybin, or another plant medicine keeps returning — quietly, persistently, over months — it's worth listening to. Do the research. Talk to people who've actually been. Find a facilitator whose approach makes you feel safer, not more excited. For readers who want to take that next step, a range of vetted ayahuasca and psychedelic retreats can be browsed on our marketplace here, with details on facilitators, medical protocols, and integration support so you can compare properly before committing. Sobriety cracks something open. Whether you fill that space with medicine, meditation, or plain old time — fill it deliberately.
Can't Stop Ruminating? Why Plant Medicine Keeps Coming Up in the Conversation
Three in the morning. Same argument playing in your head from six years ago. You know it doesn't matter. You know the person barely remembers it. And still, your brain runs the tape, frame by frame, like it's looking for a different ending. If that sounds familiar, welcome to rumination — the mental loop that turns bedtime into a courtroom and quiet moments into interrogations. It's one of the most common complaints I hear from people considering an ayahuasca retreat or a psilocybin sit. Not depression exactly. Not trauma with a capital T. Just a mind that won't shut up. Standard advice says meditate, journal, exercise, talk to someone. All of it helps. But there's a subset of people for whom the usual toolkit only takes the edge off, and they start asking harder questions. Can psychedelics help with this? Are master plants actually good for stuck thinking? What does an ayahuasca ceremony do to a ruminating brain? Let's get into it honestly. Rumination isn't a character flaw. Neuroscientists tend to blame the default mode network — the constellation of brain regions that fires up when you're not focused on a task. It's the seat of self-referential thinking, autobiographical memory, and, unfortunately, worry. In depressed and anxious brains, this network gets stuck in overdrive. The volume knob is broken. Traditional mindfulness works by giving that network something else to do. You focus on the breath, the body, a candle, a mantra — and slowly the loops loosen their grip. It's genuinely effective. Long-term meditators show measurable changes in exactly the brain regions that go haywire in chronic rumination. The catch: it takes time. Months, often years. And if the underlying loop is fed by unprocessed grief, addiction, or trauma, meditation alone can feel like bailing out a boat with a teacup. This is where a lot of people start looking at plant medicine. Here's the interesting bit. Brain-imaging studies — the ones out of Imperial College London have been the most cited — show that psilocybin and ayahuasca temporarily quiet the default mode network. That same network that keeps replaying your worst moments? It goes offline. Briefly. And in that pause, something shifts. People come out of a psilocybin session or an ayahuasca ceremony describing the same thing over and over: the loop stopped. Not forever. But long enough for them to see it from the outside, notice it wasn't them, and get some leverage on it. Researchers call this ego dissolution or psychological flexibility. Participants usually just say something like, “I finally got some space from my own head.” This isn't hype. Clinical trials for psilocybin-assisted therapy in treatment-resistant depression have shown response rates that would embarrass most conventional medications. Ayahuasca studies from Brazil and Spain point in the same direction for people who've been stuck for years. The plant medicines don't erase the pain — they seem to make it workable again. Amazonian tradition frames ayahuasca, tobacco, San Pedro, and a handful of others as master plants — plantas maestras. The idea is that each plant has something to teach, and the ceremony is less like taking a drug and more like sitting with a difficult mentor for eight hours. Take that framing however you want. What matters practically is that people leave these ceremonies with insights, not just experiences. Someone who ruminates about a failed relationship might spend the night not reliving it, but seeing it from angles they never allowed themselves. A person locked in shame about an addiction might feel, for the first time in a decade, that they're worth forgiving. Whether you call that neurochemistry, spirit, or subconscious housekeeping, the outcome is the same — the loop weakens. A few master plants that come up most in this context: Different plants, different textures. None of them are magic. All of them ask something of you. Honest answer: sometimes yes, sometimes no. Here's how I'd think about it if I were the one making the decision. A retreat probably makes sense if you've tried the standard approaches — therapy, meditation, medication, lifestyle changes — with real effort over real time, and you're still stuck. If your rumination is tied to something specific (a loss, an addiction, an event) and you sense there's material underneath that you haven't been able to touch, plant medicine can be a genuine catalyst. And if you're the kind of person who can sit with intensity, follow instructions, and take integration seriously, you're a reasonable candidate. A retreat probably isn't the right move if you're in acute crisis, on SSRIs or MAOIs (a real medical concern with ayahuasca), have a family history of psychosis or bipolar disorder, or if you're hoping the ceremony will do the work so you don't have to. It won't. The plants show you the room. You still have to clean it. Cost is a real factor too. A legitimate ayahuasca retreat in Peru runs anywhere from around $1,200 for a shorter stay to $3,500+ for a well-run ten-day program. Ibogaine treatment in Mexico, because of the medical supervision required, tends to sit between $6,000 and $10,000. Add flights, time off work, and preparation. It's not a casual purchase. The space has grown fast, and not everyone hanging a shingle knows what they're doing. Some practical filters I'd apply before sending a deposit: Here's the part that rarely makes it into the brochure. The ceremony is maybe 20% of the work. The other 80% is what you do in the weeks and months afterward — the therapy, the journaling, the slow behavior changes, the conversations you finally have. People who treat a retreat as a one-and-done fix usually find their rumination back in the door within a season. People who treat it as a starting point often report that the loops genuinely quiet down for good. Practical integration looks unglamorous. Talking to a therapist who understands psychedelic experiences. Building a sitting practice you can actually sustain (ten minutes a day beats forty minutes twice a week). Sleep. Sunlight. Real food. Fewer screens. Difficult conversations you've been avoiding. Boring, obvious, effective. If you've read this far, some part of you is already leaning in. That's worth honoring, and also worth slowing down. Talk to a doctor if you're on any medication. Talk to a therapist if you can. Read first-hand accounts, especially the difficult ones. Give yourself a few months to decide rather than a few days. Rumination is a signal, not a defect. Your mind is telling you something needs attention. Sometimes that attention comes through meditation, sometimes through therapy, sometimes through a night in a candlelit maloca with a plant that tastes like tar and a shaman singing icaros until sunrise. Different roads, same direction — a mind with a little more room in it. If something in this piece has been sitting with you, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time, ask good questions, and choose deliberately. The loop in your head has been waiting years — a few more weeks of research won't hurt it.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
